Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinomaZiad Bakouny, Srinivas R. Viswanathan, Wanling Xie et al.|Nature Communications|2021Cited by 167
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesBradley A. McGregor, Toni K. Choueiri, Rana R. McKay et al.|Journal of Clinical Oncology|2019Cited by 147
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay, Toni K. Choueiri, Dominick Bossé et al.|Cancer Immunology Research|2018Cited by 136
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean‐Christophe Pignon, Sabina Signoretti, Opeyemi A. Jegede et al.|Clinical Cancer Research|2019Cited by 121
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell CarcinomaMiriam Ficial, Sabina Signoretti, Opeyemi A. Jegede et al.|Clinical Cancer Research|2020Cited by 81